Pegylated Liposomal Doxorubicin Causes Kidney-limited Thrombotic Microangiopathy-Reference-Cited by-同舟云学术

Pegylated Liposomal Doxorubicin Causes Kidney-limited Thrombotic Microangiopathy

Published:2023-10 Issue: Volume: Page:
ISSN:0272-6386
Container-title:American Journal of Kidney Diseases
language:en
Short-container-title:American Journal of Kidney Diseases

Author:

Glezerman Ilya,Salvatore Steven,Tap William,Kelly Ciara,Brauer Ornelas Claudia Michelle,Shaikh Aisha

Publisher

Elsevier BV

Subject

Nephrology

Reference14 articles.

1. Pegylated liposomal doxorubicin: a guide to its use in various malignancies;Lyseng-Williamson;BioDrugs,2013

2. Uptake and release profiles of PEGylated liposomal doxorubicin nanoparticles: a comprehensive picture based on separate determination of encapsulated and total drug concentrations in tissues of tumor-bearing mice;Wang;Talanta,2020

3. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value;Skubitz;Cancer Chemother Pharmacol,2017

4. Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies;Uyar;Gynecol Oncol,2004

5. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes;Gabizon;Cancer Res,1994

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Doxorubicin-liposomal;Reactions Weekly;2024-04-06

2. Pharmacotherapy considerations in patients who develop acute kidney injury during anti-cancer therapy;Expert Opinion on Pharmacotherapy;2024-03-23